Transfusion Medicine/Hemostasis Clinical Research Network

描述(由申请人提供) 血液学和止血障碍是导致发病率、死亡率和入院的常见原因。NHLBI支持的输血药物止血临床试验网络(TMH-CTN)是4年前开发的，旨在构思、开发和执行基于网络的临床试验，以解决输血医学和止血方面的重要问题。凯斯西部储备大学/克利夫兰大学医院一直是这一网络的活跃成员，在申请人的指导下，在TMH-CTN的使命中发挥了重要作用。本申请的目的是描述申请者和机构的活动，并确定TMH-CTN网络在下一个资助期(如果获得资助)的方向。在此期间，该网络的任务是继续评估免疫性血小板减少性紫癜(ITP)和血栓性血小板减少性紫癜(TTP)等止血疾病的有前景的新疗法，以及新的血液产品，如血小板和血小板替代品、血小板生成素类似物和细胞因子。其他疾病包括血友病、肝素诱导的血小板减少症和自身免疫性溶血性贫血也将为进一步研究提供底物。通过定期参与以疾病为导向的小组、TMH-CTN指导委员会、对与网络相关的疾病的机构参与者的培训以及对正在进行的临床试验的监督，申请人希望通过投入个人精力和洞察力以及利用凯斯西储大学、克利夫兰大学医院和彩虹婴儿和儿童医院的临床资源，在未来几年成功地进行以网络为基础的试验，重点关注与止血和输血医学领域相关的重要疾病。

DESCRIPTION (provided by applicant) Hematologic and hemostatic disorders are common causes of morbidity, mortality and hospital admissions. The NHLBI supported Transfusion Medicine Hemostasis Clinical Trials Network (TMH-CTN) was developed 4 years ago to conceive, develop and perform network based clinical trials addressing important questions in transfusion medicine and hemostasis. Case Western Reserve University/University Hospitals of Cleveland has been an active member of this network, and under the direction of the applicant played an important role in the mission of the TMH-CTN. The purpose of this application is to describe the activities of the applicant and institution, and to define the direction of the TMH-CTN network over the next funding period, if awarded. The mission of the network over this period is to continue to evaluate promising new therapies for hemostatic disorders such as immune thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP), as well as new blood products such as platelets and platelet substitutes, thrombopoetin analogues and cytokines. Other disorders including hemophilia, heparin-induced thrombocytopenia, and autoimmune hemolytic anemia will also provide substrates for further investigation. Through regular participation in disease-oriented subgroups, the TMH-CTN steering committee, training of institutional participants in disorders relevant to the network, and oversight of ongoing clinical trials, the applicant hopes to continue to make contributions to the TMH-CTN through by devoting personal energy and insight as well as harnessing the clinical resources of Case Western Reserve University, University Hospitals of Cleveland and Rainbow Babies and Children's Hospital to successfully perform network based trials focused on important disorders relevant to the areas of hemostasis and transfusion medicine over the next years.